The latent HIV-1 reservoir in treated patients primarily consists of resting memory CD4 + T cells. Stimulating the T-cell receptor (TCR), which facilitates transition of resting into effector T cells, is the most effective strategy to purge these latently infected cells. Here we demonstrate that TCR-stimulated effector T cells still frequently harbor latent HIV-1. Renewed TCR-stimulation or subsequent activation with latency reversing agents (LRAs) did not overcome latency. However, interaction of infected effector cells with dendritic cells (DCs) triggered further activation of latent HIV-1. When compared to TCR-stimulation only, CD4 + T cells from aviremic patients receiving TCR+DC-stimulation reversed latency more frequently. Such a "one-two punch" strategy seems ideal for purging the reservoir. We determined that DC contact activates the PI3K-Akt-mTOR pathway in CD4 + T cells. This insight could facilitate the development of a novel class of potent LRAs that purge latent HIV beyond levels reached by T-cell activation. 
Introduction 41
Early on in HIV infection, cellular reservoirs containing latent HIV-1 are formed (Bruner et al., 2016) . 42
These cells contain a stably integrated and complete viral genome, but do not express sufficient 43 amounts of viral proteins to drive virus production and to be recognized by the immune system. 44
Resting memory CD4 + T cells are the main cell type harboring latent HIV-1 in patients after prolonged 45 therapy (Perelson et al., 1996; Wei et al., 1995) , but T cells with shorter half-lives, such as effector T 46 cells, can also harbor latent HIV-1 (Chavez et al., 2015; van der Sluis et al., 2013) . Latency is 47 established and maintained through multiple mechanisms that act at transcriptional and post-48 transcriptional levels (Darcis et al., 2017) . At the transcriptional level, accessibility of the HIV-1 LTR 49 promoter could be blocked in repressive chromatin structures (which can be overcome with histone 50 deacetylase (HDAC) inhibitors) or by the sequestration of transcription initiation factors such as NF-51 ĸB/NFAT/AP-1. Other blocks to HIV-1 transcription include inefficient elongation due to the lack of 52 elongation factors such as P-TEFb or the presence of negative elongation factors (NELFs). These 53 elongation factors influence the RNA polymerase complex and determine whether transcription is 54 prematurely aborted after synthesis of the trans-activation response (TAR) region or extended 55 towards the formation of full-length HIV-1 RNA transcripts. Yukl et al. recently described that HIV 56 latency at the transcriptional level occurs mainly due to inefficient RNA elongation accompanied by a 57 lack of splicing and polyadenylation factors rather than the absence of transcription initiation factors 58 4 of virus-producing cells was proposed to eliminate the reactivated cells. Stimulation of the T-cell 66 receptor (TCR) to induce the transition of resting into effector T cells is currently the most effective 67 strategy to purge latent HIV. Ex vivo stimulation of the TCR with PHA or CD3-CD28 antibodies can 68 purge approximately 1 cell per million resting memory T cells (= 1 IUPM) as determined with the gold 69 standard quantitative viral outgrowth assay (qVOA) (Ho et al., 2014) . Repeated TCR-stimulation can 70 increase this number 2-3 fold (Hosmane et al., 2017) , but based on full-genome sequencing it has 71 been estimated that the intact HIV-1 reservoir size is around 30 cells per million resting T cells in 72 treated patients (Ho et al., 2014) . This implies that T-cell activation can only purge a fraction of the 73 HIV reservoir and that additional stimuli are required to purge larger portions of latently infected 74 cells. We previously developed an HIV-1 latency assay for effector T cells and showed that 75 stimulation by DC contact efficiently purged latency (van der Sluis et al., 2013) . We now show that DC 76 contact stimulates the PI3K-Akt-mTOR pathway in effector T cells. Importantly, we demonstrate that 77 stimulation of T cells from treated aviremic patients with PHA and DCs strongly increased the 78 frequency of HIV-1 release from latently infected cells (9 out of 9 patients) compared to PHA alone (4 79 out of 9). This "one-two punch" strategy (PHA + DCs) can purge the reservoir more potently than PHA 80 treatment alone (figure 1). These findings could direct the development of novel LRA treatments that 81 also strongly stimulate the PI3K-Akt-mTor pathway. The new insights could also be used for the 82 design of a new sensitive culture-based assay to measure the intact HIV-1 reservoir. 83 hours with HIV-1. New rounds of infection and virus replication were then blocked by addition of the 90 T1249 entry inhibitor. Cells were maintained in culture for 24 hours to allow completion of reverse 91 transcription and DNA integration was allowed to proceed for 24 hours. Subsequently, the infected 92
CD4
+ T cells were co-cultured for 48 hours with or without DCs and in the presence or absence of 93 LRAs ( Figure 2A ). As shown before, the percentage of virus-producing T cells increased from 7.5% to 94 28.2% by DC co-culturing ( Figure 2B ). Reversion of latency, expressed as "fold activation" by 95 calculating the percentages of CA-p24 positive DC-treated T cells divided by control untreated T cells 96 from three independent infections, was ~3.5-fold ( Figure 2C ). Importantly, this means that for each 97 virus-producing effector T cell, 2 to 3 additional HIV-infected cells could be purged from latency by 98
DCs. Thus, a bigger part of the reservoir could be purged using DCs as an extra stimulation. The 99 observed rate of reversion of HIV-1 latency by DCs is not due to increased viral transmission or 100 integration as extending the period before addition of DCs or use of the integrase inhibitor raltegravir 101 did not change the fold activation (van der Sluis et al., 2013) . 102
To confirm involvement of the PI3K-Akt-mTOR pathway, we tested additional inhibitors that block 138 specific steps of this pathway ( Figure 5A ). The inhibitor GSK2126548 that blocks the activation of 139 PI3K, mTORC1 and mTORC2, the mTOR-inhibitor AZD8055 that blocks activation of mTORC1 and 140 mTORC2, and the Akt-inhibitor MK2206 all inhibited DC-mediated HIV-purging in a dose-dependent 141 manner ( Figure 5B-D) . These inhibitors had no effect on HIV-1 production in T-cell only cultures. We 142 used the inhibitor temsirolimus to specifically inhibit mTORC1, which inhibited DC-mediated 143 reversion of latent HIV-1 by 70% at concentrations as low as 10 nM, without any cell toxicity (Figure 144 The IκK pathway is involved in activation of the transcription factor NF-ĸB. To explore whether the 152 purging effect mediated by DCs is dependent on increased transcription initiation, we blocked 153 nuclear translocation of NF-ĸB with JSH-23 (Shin et al., 2004) , which marginally reduced DC-induced 154 HIV-1 production by ~33% at 300 nM ( Figure 6A ). Blocking c-Jun ( Figure 6B ) or c-Fos ( Figure 6C ), 155 transcription factors that bind to AP-1 and SP1 sites in the HIV-1 LTR promoter, did not affect DC-156 mediated purging. Thus, the availability of transcription factors that are important for HIV-1 gene 157 expression in activated effector T cells is sufficient and is not changed upon DC addition. 158
DCs trigger (de)phosphorylation of proteins downstream of the Akt signaling pathway 159
To explore which pathways become activated by DCs in effector T cells, we also studied the 160 phosphorylation status of 43 proteins from different signaling cascades. Seven proteins that belong 161 to the Akt signaling pathway became phosphorylated upon 2.5 hr DC contact (p38alpha, JNK1/2/3, 162 GSK-3AB, p53, CREB, c-Jun and WNK-1) (Figure 7A and 7C) . Surprisingly, two other proteins that are 163 also associated with Akt signaling, p27 and p70SK6, became dephosphorylated. It could be that these 164 kinases were dephosphorylated to prevent over-activation of the mTOR pathway via negative 165 feedback loops. Apart from the over-all activation of the Akt pathway, we also observed STAT5/6 166 proteins being less frequently phosphorylated after DC contact. We also analyzed the 167 phosphorylation status after an extended (21 hrs) DC contact. Three proteins (CREB, WNK-1 and c-168
Jun) downstream the Akt pathway still showed an increased phosphorylation status ( Figure 7B . Although RNA could be detected for all patients with the double treatment, the levels of RNA 213 released were not increased. This could be caused by efficient capture and degradation of free HIV-1 214
by DCs which will limit the amount of HIV-1 RNA to be detected in supernatant (van Montfort et al., induced in T cells pretreated with PHA. Our data illustrate that formation of tetraspanin-enriched 219 microdomains (TEMs) between DCs and T cells is important for the purging ability of DCs ( Figure 3A ) 220 (Berditchevski et al., 1997; Lin and Fan, 2016; Mittelbrunn et al., 2002; Rocha-Perugini et al., 2016) . 221
These TEMs recruit PI4K to the membrane to locally produce phosphoinositols, such as 222 phosphatidylinositol-4,5 bisphosphate (PtdIns(4,5)P 2 ), which activate RAS via Shc proteins (Hemler, 223 2005; Pawson and Scott, 1997) . Active RAS can activate the MEK-ERK, PLC-PKC and the PI3K-Akt-224 mTOR pathway. The DC-mediated HIV-1 purging in T cells, however was predominantly caused by 225 activation of the PI3K-Akt-mTOR pathway, which is associated with improved RNA elongation, 226 ribosomal activity, protein synthesis and cell survival (Darcis et al., 2015) . Thus, activation of the 227 PI3K-Akt-mTOR probably overcomes post-transcriptional blocks to form infectious viral particles. 228
Whether activation of this pathway is strictly regulated via RAS activation or via other DC-T cell 229 mediated interactions needs to be explored in future research. 230
We hypothesize that phosphoinositols, especially the availability of PtdIns(4,5)P 2 , determines HIV-1 231 latency at various levels ( Figure 9 ). First, transcription factors such as NF-ĸB or c-Jun/c-Fos are 232 required for HIV-1 transcription initiation (Bullen et al., 2014; Darcis et al., 2015; Laird et al., 2015) . 233
These factors are upregulated via the MEK-ERK and PLC-PKC pathway, where PtdIns(4,5)P 2 is 234 converted by PLC into IP 3 and DIAG (Mendoza et al., 2011) . This can be achieved by TCR stimulation 235 or PKC activators. Second, PI3K-Akt-mTor pathway activation is required to allow transcriptional 236 elongation and protein synthesis. DCs can initiate this pathway by PtdIns(4,5)P 2 production in TEMs 237 via PI4K activation and subsequent phosphorylation into PtdIns(3,4,5)P 3 by PI3K. Since the PI3K-Akt-238 mTOR and PLC-PKC pathway either phosphorylate or dephoshorylate PtdIns(4,5)P 2 , strong activation 239 of either one of these pathways will directly inhibit the activation of the other pathway. Thus, a fine 240 balance between these pathways should be pursued to purge latent HIV-1, or both pathways should 241 be activated sequentially as achieved for instance with our "one-two punch" strategy, in which, after
In this light it is not surprising that TCR stimulation, which can trigger sub-optimally the PLC-PKC and 244 PI3K-Akt-mTOR pathway, has some HIV-1 purging ability, leading to outgrowth of infectious particles, 245 whereas solely activating the transcription initiation route does not (Bullen et al., 2014) . 246
Interestingly, a recent study discovered the importance of the mTOR pathway in purging latent HIV-1 247 in resting cells (Besnard et al., 2016) . Specifically blocking the mTOR pathway after TCR stimulation 248 negated reversal of latency in patient cells, illustrating that TCR-stimulation can sub-optimally 249 activate this pathway. Our results extend those data by showing that DCs activate this PI3K-Akt-250 mTOR pathway stronger than TCR stimulation, leading to increased purging efficiency. 251
Blocking multiple targets in the PI3K-Akt-mTOR pathway, for instance with GSK2126458, inhibited 252 DC-specific activation of the PI3K-AKt-mTOR pathway better than the mTORC1 inhibitor 253
temsirolimus. This is in agreement with a study from Martin et al., who reported that the mTORC1 254 inhibitor rapamycin (Calne et al., 1989; Ernst et al., 1989) contact might be more efficient in tissues, which could result in the observed low levels of ongoing 275 virus production, even in the presence of therapy (Lorenzo-Redondo et al., 2016; Pasternak et al., 276 2012; Sigal et al., 2011) . 277
Interestingly, Gramatica and colleagues already raised the possibility that latency reversal might be 278 more effective in lymphoid tissues where contact of T cells with DCs is more prominent than in blood 279 (Gramatica, A; Greene, WC; Montano, 2015) . The lack of efficacy of clinical trials using LRAs aimed at 280 decreasing the HIV-1 reservoir size might therefore be caused by the fact that the reservoir was 281 analysed only in the peripheral blood and not in tissues, where preferential DC-mediated purging 282 could occur (Archin et al., 2012; Gutiérrez et al., 2016; Rasmussen et al., 2018; Søgaard et al., 2015; 283 Spivak et al., 2014) . One approach to use DCs to increase the LRA purging efficiency in patients might 284 be the combination of an LRA with a specific TLR agonists that will direct DCs to tissues, where latent 285 reservoirs are maintained. The use of DCs as a natural mechanism to revert HIV-1 latency has limited 286 side effects (Palucka and Banchereau, 2013) , as compared to T cell receptor agonists (Prins et al., 287 1999) . 288
Our results have important implications. Firstly, the potent capacity of DCs to reactivate HIV-1 289 proviruses which were not purged despite PHA stimulation could be used to design a more sensitive 290 culture-based assay to measure the replication-competent reservoir, for instance by adapting thehighlights the need to look at tissue reservoirs when possible, since cell-to-cell contact appears to be 293 a major factor controlling HIV-1 latency. Finally, our results further support the importance of the 294 PI3K-Akt-mTOR pathway in HIV-1 latency. These novel insights could be used to develop more 295 efficient LRA strategies in the quest to get rid of the latent HIV-1 reservoir. 296 297
Materials and methods 298
Reagents. The fusion inhibitor T1249 was obtained from Pepscan (Therapeutics BV, Lelystad, The 299 Netherlands) and used at a final concentration of 0.1 μg/ml. Antibodies against CD9, CD63, CD81, 300 CD83, CD86, CD151, CD45RO, CD45RA, were purchased from Biolegend (San Diego, CA, USA). Other 301 antibodies are directed against CA-p24 (clone KC-57RD1) (Beckman Coulter, Brea, CA, USA) and CD3-302 APC (BD Pharmingen, Breda, the Netherlands). 303
Cells. Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats (Central 304
Laboratory Blood Bank, Amsterdam, The Netherlands) by use of a Ficoll gradient and frozen in 305 multiple vials. When required, PBMCs were thawed, activated with phytohaemagglutinin (PHA, 306
Remel, 2 μg/ml) and cultured in RPMI medium supplemented with 10% FCS and recombinant human 307 IL-2 (rhIL-2, Novartis, 100 U/ml). On day 2 of culture, CD8 + T lymphocytes were depleted using CD8 308 immunomagnetic beads (Dynal, Invitrogen, Carlsbad, CA, USA) and the CD4 + -enriched T lymphocytes 309 were cultured for 3 more days. SupT1 CCR5 expressing T cells, a kind gift of prof. J. Hoxie (Del Prete 310 et al., 2009), were cultured in RPMI 1640 medium containing 10% FCS. 311
Monocytes were isolated from PBMCs with CD14 magnetic beads from Miltenyi Biotec (GmbH, 312
Bergisch Gladbach, Germany) according to the manufacturer's protocol. Purified monocytes were 313 cultured in RPMI 1640 medium containing 10% FCS and differentiated into monocyte-derived DCs by 314 stimulation with 45 ng/ml interleukin-4 (rIL-4; Biosource, Nivelles, Belgium) and 500 U/mlgranulocyte macrophage colony-stimulating factor (GM-CSF; Schering-Plough, Brussels, Belgium) on 316 day 0 and 2, and used on day 6 (van Montfort et al., 2008) . 317 HEK 293T cells were grown as a monolayer in Dulbecco's minimal essential medium (Gibco, BRL, 318
Gaithersburg, MD) supplemented with 10% (v/v) fetal calf serum (FCS), 40 U/ml penicillin, 40 μg/ml 319 streptomycin at 37°C and 5% CO 2 . 320 protocol. ~1.4-2.0 x 10 6 cells were treated with 2 µg/ml PHA, heterologous monocyte-derived DCs in 374 a 1:3 ratio (DC:T), PHA combined with DCs (1:3 ratio) or left untreated for 72 hrs in RPMI1640 375 medium containing rhIL-2 and 80 ng/ml sanquinavir. Cell-free supernatant was collected by 376 centrifugation for 5 min at 500 rcf. Extracellular HIV-1 RNA was isolated from 300 microliters of the 377 supernatant using the Boom isolation method (Boom et al., 1990 ) with the addition of 2 micrograms 378 of carrier RNA (poly A RNA, Qiagen, Venlo, The Netherlands) and processed for reverse transcription 379 and first PCR using QIAGEN® OneStep RT-PCR kit (Qiagen, Venlo, The Netherlands) according to the 380 manufacturer's instructions. The primers used were TAR-F (5'-GGGTCTCTCTGGTTAGACCAG-3') and 381 HIV-FOR (Malnati et al., 2008) . The PCR settings were as follows: 94°C for 3 min, followed by 15 382 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, followed by 72°C for 10 min. Two microliters 383 of the first PCR product were subsequently used as a template in the second, semi-nested, real-time, 384 PCR amplification, performed using the primers and a TaqMan probe described by Malnati et al. 385 (Malnati et al., 2008) . 386 387 qVOA with 1) PHA, 2) DC one-two punch 388 Isolated CD4 T cells from aviremic patients were activated with 2 µg/ml PHA for 72 hrs in RPMI1640 389 medium containing rhIL-2 and 100 ng/ml entry inhibitor T1249. Cells were washed three times and 390 cultured in 96-well plate with a cell density of 2. Huang, J., Wang, F., Argyris, E., Chen, K., Liang, Z., Tian, H., Huang, W., Squires, K., Verlinghieri, G., 465 and Zhang, H. (2007) . Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+T 466 lymphocytes. Nat. Med. 13, 1241 Med. 13, -1247 Kieffer, T.L., Kwon, P., Nettles, R.E., Han, Y., Ray, S.C., and Siliciano, R. Spivak, A.M., Andrade, A., Eisele, E., Hoh, R., Bacchetti, P., Bumpus, N.N., Emad, F., Buckheit, R., 548
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